Nike, Inc. - Class B logo

Nike, Inc. - Class B (NKE)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
37. 13
-0.01
-0.0269%
$
55.16B Market Cap
27.8 P/E Ratio
1.64% Div Yield
30.9M Volume
3.76 Eps
$ 37.14
Previous Close
Add Transaction
Day Range
36.91 37.87
Year Range
31.97 70.44
Want to track NKE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NIKE's Classic Franchises Fade: Can Fresh Launches Drive Recovery?

NIKE's Classic Franchises Fade: Can Fresh Launches Drive Recovery?

NKE faces a $1B hit from fading classics but bets on fresh launches and sport-led innovation to spark recovery.

Zacks | 1 year ago
NIKE: Patience Will Be Rewarded

NIKE: Patience Will Be Rewarded

Despite near-term EPS headwinds and China/wholesale uncertainty, I reiterate my Buy rating on Nike for long-term investors. Short-term challenges, including tariffs and negative EPS revisions, are likely temporary. Nike's strong ROCE and reinvestment rates support double-digit long-term growth even under my more conservative projections.

Seekingalpha | 1 year ago
NIKE vs. Skechers: Which Player is Ahead in the Global Footwear Race?

NIKE vs. Skechers: Which Player is Ahead in the Global Footwear Race?

NKE emphasizes innovation and cultural scale, while SKX expands globally with comfort and value-driven growth.

Zacks | 1 year ago
Nike (NKE) Stock Declines While Market Improves: Some Information for Investors

Nike (NKE) Stock Declines While Market Improves: Some Information for Investors

Nike (NKE) closed the most recent trading day at $76.39, moving 1.05% from the previous trading session.

Zacks | 1 year ago
“What do you say when somebody says they want to give you $2 billion?” Nike co-founder Phil Knight makes a record donation.

“What do you say when somebody says they want to give you $2 billion?” Nike co-founder Phil Knight makes a record donation.

Knight and his wife are making a record private gift to Oregon Health & Science University amid broader battles over public funding for higher education.

Wsj | 1 year ago
Nike co-founder Phil Knight to donate $2 billion to OHSU cancer institute

Nike co-founder Phil Knight to donate $2 billion to OHSU cancer institute

The Knight Foundation said the gift that will be used to shift the scientific approach to cancer treatment, research and patient care outcomes.

Cnbc | 1 year ago
Nike co-founder Phil Knight to donate $2 billion to University of Oregon's Cancer Institute

Nike co-founder Phil Knight to donate $2 billion to University of Oregon's Cancer Institute

Nike co-founder Phil Knight is donating $2 billion to the Oregon Health and Science University's Cancer Institute. The Knight Foundation says it's the single largest donation ever to a U.S. university, college or health institution.

Cnbc | 1 year ago
Here is What to Know Beyond Why NIKE, Inc. (NKE) is a Trending Stock

Here is What to Know Beyond Why NIKE, Inc. (NKE) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Nike (NKE). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
NIKE Bets on EMEA Growth: Can This Strategy Pay Off in FY26?

NIKE Bets on EMEA Growth: Can This Strategy Pay Off in FY26?

NKE's EMEA strategy drives growth by building on marketplace streamlining and boosting NIKE Digital through an integrated channel approach.

Zacks | 1 year ago
NIKE's E-Commerce Momentum Builds: Is it Enough to Offset Retail Woes?

NIKE's E-Commerce Momentum Builds: Is it Enough to Offset Retail Woes?

NKE's digital push gains pace with premium online strategies, but retail softness and China recovery remain hurdles.

Zacks | 1 year ago
JD Sport: A cut price way of coat-tailing on Nike's return to form?

JD Sport: A cut price way of coat-tailing on Nike's return to form?

JD Sports Fashion PLC (LSE:JD.) has long ridden in Nike's slipstream.

Proactiveinvestors | 1 year ago
Nike Offers A Step Up In Value From Here

Nike Offers A Step Up In Value From Here

Nike's fundamentals have deteriorated, but recent management changes and innovation efforts offer a path to recovery and renewed growth. Despite significant stock appreciation, I see further, though more modest, upside potential, justifying my continued soft "buy" rating. Valuation is elevated versus peers, but only modest profit and cash flow improvements are needed for fair value based on historical norms.

Seekingalpha | 1 year ago
Loading...
Load More